Investigational Drug Information for Quisinostat
✉ Email this page to a colleague
What is the drug development status for Quisinostat?
Quisinostat is an investigational drug.
There have been 3 clinical trials for Quisinostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Janssen Pharmaceutica N.V., Belgium, NewVac LLC, and Janssen Research & Development, LLC.
Summary for Quisinostat
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 412 |
| WIPO Patent Applications | 375 |
| Japanese Patent Applications | 96 |
| Clinical Trial Progress | Phase 2 (2015-09-01) |
| Vendors | 0 |
Recent Clinical Trials for Quisinostat
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | Janssen Pharmaceutica N.V., Belgium | Phase 2 |
| Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | NewVac LLC | Phase 2 |
| Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | Janssen Pharmaceutica N.V., Belgium | Phase 1 |
Clinical Trial Summary for Quisinostat
Top disease conditions for Quisinostat
Top clinical trial sponsors for Quisinostat
US Patents for Quisinostat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
